Shares of ResMed Inc. RMD rallied 1.61% to $237.13 Thursday, on what proved to be an all-around poor trading session for the ...

Shares of ResMed Inc. RMD rose 1.12% to $239.78 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and the ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

In the latest quarter, 5 analysts provided ratings for ResMed RMD, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

ResMed actually specializes in ventilators, for example against sleep apnoea. Now comes the first end customer product for ...

ResMed shares slumped and Eli Lilly shares gained after the FDA approved Eli Lilly's weight-loss treatment Zepbound for some patients with sleep apnea. Major U.S. indexes were mixed at midday ...

Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...